SII Awaits Govt Approval To Conduct Trials Of Novavax COVID Vaccine

The Serum Institute of India has applied to the Drugs Controller General of India seeking permission to conduct domestic trials of ‘Novavax’ coronavirus vaccine. Reportedly, the US-based company claimed that Novavax showed 89.3% and 60% effectiveness during the trials in the UK and Africa respectively. Earlier, Novavax and SII collaborated to produce 2 billion vaccine doses. Besides, Novavax has received around $388 million from the Coalition for Epidemic Preparedness Innovation.